OBI Pharma, Inc
10
2
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.0%
3 terminated/withdrawn out of 10 trials
40.0%
-46.5% vs industry average
10%
1 trials in Phase 3/4
150%
3 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Role: lead
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Role: lead
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Role: lead
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Role: lead
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
Role: lead
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Role: lead
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
Role: lead
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Role: lead
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Role: lead
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
Role: collaborator
All 10 trials loaded